Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Foresight Diagnostics on the transaction. Allogene Therapeutics Inc. (Nasdaq: ALLO) and Foresight Diagnostics, announced a strategic partnership to develop a minimal residual...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Cleva in the transaction. Nigerian fintech company Cleva, announced it has raised $1.5 million in pre-Seed funding. The round was led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Hyperexponential in the transaction. Osborne Clarke advised Highland Europe. Hyperexponential announced the closing of its $73 million Series B funding round led...
You must be a Standard 1 Year member to access this content.
Goodwin advised Renesas Electronics Corporation on the acquisition of Transphorm, assisted by Wilson Sonsini Goodrich & Rosati. On January 11, 2024, Renesas Electronics Corporation (Renesas, TSE:...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati acted as Concord Healthcare’s U.S. and Hong Kong counsel in the IPO and SEHK listing. Concord Medical Services Holdings Limited (“Concord...
You must be a Standard 1 Year member to access this content.
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich and Rosati is representing On.Energy on the transaction. On.Energy announced the closing of both construction facility totaling more than $40 million and permanent...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised MarketAxess on the transaction. Broadwind (NASDAQ: BWEN) announced that it had entered into a definitive Tax Credit Transfer Agreement with...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised C4 Therapeutics on the transaction. C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) announced that it has entered into an exclusive license...
You must be a Standard 1 Year member to access this content.
